Apimeds Pharmaceuticals US, Inc. (APUS)
NYSEAMERICAN: APUS · Real-Time Price · USD
1.890
-0.040 (-2.07%)
Sep 29, 2025, 3:16 PM EDT - Market open
Company Description
Apimeds Pharmaceuticals US, Inc. operates as a clinical stage biopharmaceutical company in the United States.
It researches, develops, manufactures, commercializes, and sells Apitox, a purified, pharmaceutical grade venom of the Apis mellifera, or honeybee for the treatment of inflammation and pain management symptoms associated with osteoarthritis and multiple sclerosis.
The company has a strategic alliance with University of Alabama for the development of ai² future labs program.
The company was incorporated in 2020 and is based in Matawan, New Jersey.
Apimeds Pharmaceuticals US, Inc.
| Country | United States |
| Founded | 2020 |
| IPO Date | May 9, 2025 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Erik Emerson |
Contact Details
Address: 100 Matawan Road, Suite 325 Matawan, New Jersey 07747 United States | |
| Phone | 848 201 5010 |
| Website | apimedsus.com |
Stock Details
| Ticker Symbol | APUS |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 0001894525 |
| CUSIP Number | 03771D102 |
| ISIN Number | US03771D1028 |
| Employer ID | 85-1099700 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Erik C. Emerson | Chief Executive Officer and Director |
| Dr. Christopher M. H. Kim M.D. | Chief Medical Officer and Chairman |
| Erick J. Frim | Chief Financial Officer |
| Brian Peters | Head of Proprietary AI Division |
| Dr. Susan M. Kramer Dr. P.H. | Senior Vice President of Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 19, 2025 | 10-Q | Quarterly Report |
| Aug 14, 2025 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Jul 16, 2025 | 8-K | Current Report |
| Jun 5, 2025 | 8-K | Current Report |
| May 23, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 20, 2025 | 8-K | Current Report |
| May 20, 2025 | 10-Q | Quarterly Report |
| May 19, 2025 | SCHEDULE 13D | Filing |
| May 15, 2025 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| May 12, 2025 | 8-K | Current Report |